Name：Bin Cao
Email：
caobin_ben@163.com
Research Interest:
Prof. Bin Cao and his team have been dedicated to answering key questions in the field of respiratory infection and emerging infectious diseases. His major research field includes:
1. Epidemiology, clinical characteristics, and treatment of viral pneumonia;
2. Molecular and cellular basis of the pathogenesis of influenza viruses;
3. Pathogenesis and molecular mechanism of viral sepsis;
4. Diagnosis and treatment strategy and drug resistance of drug-resistant pathogens.
Selected Publications
1. J. Yu, H. Li, J. Jia, Z. Huang, S. Liu, Y. Zheng, S. Mu, X. Deng, X. Zou, Y. Wang, X. Shang, D. Cui, L. Huang, X. Feng, W. J. Liu and B. Cao: Pandemic influenza A (H1N1) virus causes abortive infection of primary human T cells. Emerg Microbes Infect, 1-35 (2022)
2. L. Huang, Q. Yao, X. Gu, Q. Wang, L. Ren, Y. Wang, P. Hu, L. Guo, M. Liu, J. Xu, X. Zhang, Y. Qu, Y. Fan, X. Li, C. Li, T. Yu, J. Xia, M. Wei, L. Chen, Y. Li, F. Xiao, D. Liu, J. Wang, X. Wang and B. Cao: 1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study. Lancet, 398(10302), 747-758 (2021)
3. H. Li, L. Liu, D. Zhang, J. Xu, H. Dai, N. Tang, X. Su and B. Cao: SARS-CoV-2 and viral sepsis: observations and hypotheses. Lancet, 395(10235), 1517-1520 (2020)
4. Y. Wang, D. Zhang, G. Du, R. Du, J. Zhao, Y. Jin, S. Fu, L. Gao, Z. Cheng, Q. Lu, Y. Hu, G. Luo, K. Wang, Y. Lu, H. Li, S. Wang, S. Ruan, C. Yang, C. Mei, Y. Wang, D. Ding, F. Wu, X. Tang, X. Ye, Y. Ye, B. Liu, J. Yang, W. Yin, A. Wang, G. Fan, F. Zhou, Z. Liu, X. Gu, J. Xu, L. Shang, Y. Zhang, L. Cao, T. Guo, Y. Wan, H. Qin, Y. Jiang, T. Jaki, F. G. Hayden, P. W. Horby, B. Cao and C. Wang: Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet, 395(10236), 1569-1578 (2020)
5. B. Cao, Y. Wang, D. Wen, W. Liu, J. Wang, G. Fan, L. Ruan, B. Song, Y. Cai, M. Wei, X. Li, J. Xia, N. Chen, J. Xiang, T. Yu, T. Bai, X. Xie, L. Zhang, C. Li, Y. Yuan, H. Chen, H. Li, H. Huang, S. Tu, F. Gong, Y. Liu, Y. Wei, C. Dong, F. Zhou, X. Gu, J. Xu, Z. Liu, Y. Zhang, H. Li, L. Shang, K. Wang, K. Li, X. Zhou, X. Dong, Z. Qu, S. Lu, X. Hu, S. Ruan, S. Luo, J. Wu, L. Peng, F. Cheng, L. Pan, J. Zou, C. Jia, J. Wang, X. Liu, S. Wang, X. Wu, Q. Ge, J. He, H. Zhan, F. Qiu, L. Guo, C. Huang, T. Jaki, F. G. Hayden, P. W. Horby, D. Zhang and C. Wang: A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med, 382(19), 1787-1799 (2020)
6. F. Zhou, T. Yu, R. Du, G. Fan, Y. Liu, Z. Liu, J. Xiang, Y. Wang, B. Song, X. Gu, L. Guan, Y. Wei, H. Li, X. Wu, J. Xu, S. Tu, Y. Zhang, H. Chen and B. Cao: Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet, 395(10229), 1054-1062 (2020)
7. C. Huang, Y. Wang, X. Li, L. Ren, J. Zhao, Y. Hu, L. Zhang, G. Fan, J. Xu, X. Gu, Z. Cheng, T. Yu, J. Xia, Y. Wei, W. Wu, X. Xie, W. Yin, H. Li, M. Liu, Y. Xiao, H. Gao, L. Guo, J. Xie, G. Wang, R. Jiang, Z. Gao, Q. Jin, J. Wang and B. Cao: Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 395(10223), 497-506 (2020)
8. H. Li, X. Gu, H. Li, F. Gong, J. Xu, Y. Wang, H. Li, S. Ruan, Q. Yang and B. Cao: Risk Factors of Viral RNAaemia and Its Association With Clinical Prognosis Among Patients With Severe COVID-19. Chest, 159(4), 1382-1386 (2021)
9. J. Xu, Y. Teng, L. Shang, X. Gu, G. Fan, Y. Chen, R. Tian, S. Zhang and B. Cao: The Effect of Prior Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Treatment on Coronavirus Disease 2019 (COVID-19) Susceptibility and Outcome: A Systematic Review and Meta-analysis. Clin Infect Dis, 72(11), e901-e913 (2021)
10. H. Li, X. Cui, L. Sun, X. Deng, S. Liu, X. Zou, B. Li, C. Wang, Y. Wang, Y. Liu, B. Lu and B. Cao: High concentration of Cas12a effector tolerates more mismatches on ssDNA. Faseb j, 35(1), e21153 (2021)
11. S. Duan, X. Gu, G. Fan, F. Zhou, G. Zhu and B. Cao: C-reactive protein or procalcitonin combined with rhinorrhea for discrimination of viral from bacterial infections in hospitalized adults in non-intensive care units with lower respiratory tract infections. BMC Pulm Med, 21(1), 308 (2021)
12. J. Zhao, Y. Zhang, Y. Fan, J. Han, Z. Xiong, X. Liu, B. Li, B. Lu and B. Cao: Characterization of an NDM-5-producing hypervirulent Klebsiella pneumoniae sequence type 65 clone from a lung transplant recipient. Emerg Microbes Infect, 10(1), 396-399 (2021)
13. Z. Liu, Y. Li, X. Tian, Q. Liu, E. Li, X. Gu, M. Liu, J. Xu, Z. He, Y. Huang, S. Xu, G. Lai, Y. Chen, X. Zhang, T. Zhang, J. Xu, L. Zhu, J. Qu and B. Cao: Airway-invasion-associated pulmonary computed tomography presentations characteristic of invasive pulmonary Aspergillosis in non-immunocompromised adults: a National Multicenter Retrospective Survey in China. Respir Res, 21(1), 173 (2020)
14. Y. Wang, W. Zhong, A. Salam, J. Tarning, Q. Zhan, J. A. Huang, H. Weng, C. Bai, Y. Ren, K. Yamada, D. Wang, Q. Guo, Q. Fang, S. Tsutomu, X. Zou, H. Li, A. Gillesen, L. Castle, C. Chen, H. Li, J. Zhen, B. Lu, J. Duan, L. Guo, J. Jiang, R. Cao, G. Fan, J. Li, F. G. Hayden, C. Wang, P. Horby and B. Cao: Phase 2a, open-label, dose-escalating, multi-center pharmacokinetic study of favipiravir (T-705) in combination with oseltamivir in patients with severe influenza. EBioMedicine, 62, 103125 (2020)
15. F. Zhou, Y. Wang, Y. Liu, X. Liu, L. Gu, X. Zhang, Z. Pu, G. Yang, B. Liu, Q. Nie, B. Xue, J. Feng, Q. Guo, J. Liu, H. Fan, J. Chen, Y. Zhang, Z. Xu, M. Pang, Y. Chen, X. Nie, Z. Cai, J. Xu, K. Peng, X. Li, P. Xiang, Z. Zhang, S. Jiang, X. Su, J. Zhang, Y. Li, X. Jin, R. Jiang, J. Dong, Y. Song, H. Zhou, C. Wang and B. Cao: Disease severity and clinical outcomes of community-acquired pneumonia caused by non-influenza respiratory viruses in adults: a multicentre prospective registry study from the CAP-China Network. Eur Respir J, 54(2) (2019)
16. X. Jia, B. Liu, L. Bao, Q. Lv, F. Li, H. Li, Y. An, X. Zhang, B. Cao and C. Wang: Delayed oseltamivir plus sirolimus treatment attenuates H1N1 virus-induced severe lung injury correlated with repressed NLRP3 inflammasome activation and inflammatory cell infiltration. PLoS Pathog, 14(11), e1007428 (2018)
17. H. Li, K. C. Bradley, J. S. Long, R. Frise, J. W. Ashcroft, L. C. Hartgroves, H. Shelton, S. Makris, C. Johansson, B. Cao and W. S. Barclay: Internal genes of a highly pathogenic H5N1 influenza virus determine high viral replication in myeloid cells and severe outcome of infection in mice. PLoS Pathog, 14(1), e1006821 (2018)
18. B. Cao, G. H. Huang, Z. H. Pu, J. X. Qu, X. M. Yu, Z. Zhu, J. P. Dong, Y. Gao, Y. X. Zhang, X. H. Li, J. H. Liu, H. Wang, Q. Xu, H. Li, W. Xu and C. Wang: Emergence of community-acquired adenovirus type 55 as a cause of community-onset pneumonia. Chest, 145(1), 79-86 (2014)
19. C. Wang, B. Cao, Q. Q. Liu, Z. Q. Zou, Z. A. Liang, L. Gu, J. P. Dong, L. R. Liang, X. W. Li, K. Hu, X. S. He, Y. H. Sun, Y. An, T. Yang, Z. X. Cao, Y. M. Guo, X. M. Wen, Y. G. Wang, Y. L. Liu and L. D. Jiang: Oseltamivir compared with the Chinese traditional therapy maxingshigan-yinqiaosan in the treatment of H1N1 influenza: a randomized trial. Ann Intern Med, 155(4), 217-25 (2011)
20. B. Cao, X. W. Li, Y. Mao, J. Wang, H. Z. Lu, Y. S. Chen, Z. A. Liang, L. Liang, S. J. Zhang, B. Zhang, L. Gu, L. H. Lu, D. Y. Wang and C. Wang: Clinical features of the initial cases of 2009 pandemic influenza A (H1N1) virus infection in China. N Engl J Med, 361(26), 2507-17 (2009)